scholarly journals Easipro3 – Enhancing Satisfaction With Prostate Cancer Treatment Decision With The Mobile Health Program Prostana: A Multicenter Randomized Controlled Trial

2017 ◽  
Vol 20 (9) ◽  
pp. A504 ◽  
Author(s):  
S Vosgerau ◽  
D Urbanski ◽  
P Kollenbach ◽  
M Schöne ◽  
M Gedamke ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Randomized Controlled Trial ◽  
Cancer Treatment ◽  
Mobile Health ◽  
Health Program ◽  
Controlled Trial ◽  
Treatment Decision ◽  
Prostate Cancer Treatment ◽  
Randomized Controlled ◽  
Multicenter Randomized Controlled Trial

scholarly journals Effects of a Water, Sanitation, and Hygiene Mobile Health Program on Diarrhea and Child Growth in Bangladesh: A Cluster-randomized Controlled Trial of the Cholera Hospital-based Intervention for 7 Days (CHoBI7) Mobile Health Program

2020 ◽  
Author(s):  
Christine Marie George ◽  
Shirajum Monira ◽  
Fatema Zohura ◽  
Elizabeth D Thomas ◽  
M Tasdik Hasan ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Mobile Health ◽  
Health Program ◽  
Controlled Trial ◽  
Home Visits ◽  
Facility Delivery ◽  
Health Facility Delivery ◽  
Randomized Controlled ◽  
Diarrhea Patient ◽  
Cluster Randomized

Abstract Background The Cholera Hospital-Based Intervention for 7 Days (CHoBI7) mobile health (mHealth) program was a cluster-randomized controlled trial of diarrhea patient households conducted in Dhaka, Bangladesh. Methods Patients were block-randomized to 3 arms: standard message on oral rehydration solution use; health facility delivery of CHoBI7 plus mHealth (no home visits); and health facility delivery of CHoBI7 plus 2 home visits and mHealth. The primary outcome was reported diarrhea in the past 2 weeks collected monthly for 12 months. The secondary outcomes were stunting, underweight, and wasting at a 12-month follow-up. Analysis was intention-to-treat. Results Between 4 December 2016 and 26 April 2018, 2626 participants in 769 households were randomly allocated to 3 arms: 849 participants to the standard message arm, 886 to mHealth with no home visits arm, and 891 to the mHealth with 2 home visits. Children <5 years had significantly lower 12-month diarrhea prevalence in both the mHealth with 2 home visits arm (prevalence ratio [PR]: 0.73 [95% confidence interval {CI}, .61–.87]) and the mHealth with no home visits arm (PR: 0.82 [95% CI, .69–.97]). Children <2 years were significantly less likely to be stunted in both the mHealth with 2 home visits arm (33% vs 45%; odds ratio [OR]: 0.55 [95% CI, .31–.97]) and the mHealth with no home visits arm (32% vs 45%; OR: 0.54 [95% CI, .31–.96]) compared with children in the standard message arm. Conclusions The CHoBI7 mHealth program lowered pediatric diarrhea and stunting among diarrhea patient households. Clinical Trials Registration NCT04008134.

scholarly journals Employing a mobile health decision aid to improve decision-making for patients with advanced prostate cancer and their decision partners/proxies: the CHAMPION randomized controlled trial study design

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Lourdes R. Carhuapoma ◽  
Winter M. Thayer ◽  
Catherine E. Elmore ◽  
Jane Gildersleeve ◽  
Tanmay Singh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Decision Making ◽  
Randomized Controlled Trial ◽  
Decision Support ◽  
Cancer Patients ◽  
Mobile Health ◽  
Advanced Prostate Cancer ◽  
Controlled Trial ◽  
Minority Populations ◽  
Randomized Controlled

Abstract Background Metastatic prostate cancer remains a lethal malignancy that warrants novel supportive interventions for patients and their decision partners and proxies. Decision aids have been applied primarily to patients with localized disease, with minimal inclusion of patients with advanced prostate cancer and their decision partners. The use of a community patient navigator (CPN) has been shown to have a positive supportive role in health care, particularly with individuals from minority populations. Research is needed to evaluate decision support interventions tailored to the needs of advanced prostate cancer patients and their decision partners in diverse populations. Methods Guided by Janis and Mann’s Conflict Model of Decision Making, the Cancer Health Aid to Manage Preferences and Improve Outcomes through Navigation (CHAMPION) is a randomized controlled trial to assess the feasibility and acceptability of a mobile health (mHealth), CPN-administered decision support intervention designed to facilitate communication between patients, their decision partners, and the healthcare team. Adult prostate cancer patients and their decision partners at three mid-Atlantic hospitals in the USA were randomized to receive enhanced usual care or the decision intervention. The CHAMPION intervention includes a theory-based decision-making process tutorial, immediate and health-related quality of life graphical summaries over time (using mHealth), values clarification via a balance sheet procedure with the CPN support during difficult decisions, and facilitated discussions with providers to enhance informed, shared decision-making. Discussion The CHAMPION intervention is designed to leverage dynamic resources, such as CPN teams, mHealth technology, and theory-based information, to support decision-making for advanced prostate cancer patients and their decision partners. This intervention is intended to engage decision partners in addition to patients and represents a novel, sustainable, and scalable way to build on individual and community strengths. Patients from minority populations, in particular, may face unique challenges during clinical communication. CHAMPION emphasizes the inclusion of decision partners and CPNs as facilitators to help address these barriers to care. Thus, the CHAMPION intervention has the potential to positively impact patient and decision partner well-being by reducing decisional conflict and decision regret related to complex, treatment-based decisions, and to reduce cancer health disparities. Trial registration ClinicalTrials.govNCT03327103. Registered on 31 October 2017—retrospectively registered. World Health Organization Trial Registration Data Set included in Supplementary Materials.

scholarly journals Mobile Health App (AGRIPPA) to Prevent Relapse After Successful Interdisciplinary Treatment for Patients With Chronic Pain: Protocol for a Randomized Controlled Trial (Preprint)

2020 ◽  
Author(s):  
Stefan Elbers ◽  
Jan Pool ◽  
Harriët Wittink ◽  
Albère Köke ◽  
Else Scheffer ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Randomized Controlled Trial ◽  
Mobile Health ◽  
Treatment Program ◽  
Treatment Condition ◽  
Controlled Trial ◽  
Interdisciplinary Treatment ◽  
Randomized Controlled ◽  
Multicenter Randomized Controlled Trial ◽  
Over Time

BACKGROUND To facilitate adherence to adaptive pain management behaviors after interdisciplinary multimodal pain treatment, we developed a mobile health app (AGRIPPA app) that contains two behavior regulation strategies. OBJECTIVE The aims of this project are (1) to test the effectiveness of the AGRIPPA app on pain disability; (2) to determine the cost-effectiveness; and (3) to explore the levels of engagement and usability of app users. METHODS We will perform a multicenter randomized controlled trial with two parallel groups. Within the 12-month inclusion period, we plan to recruit 158 adult patients with chronic pain during the initial stage of their interdisciplinary treatment program in one of the 6 participating centers. Participants will be randomly assigned to the standard treatment condition or to the enhanced treatment condition in which they will receive the AGRIPPA app. Patients will be monitored from the start of the treatment program until 12 months posttreatment. In our primary analysis, we will evaluate the difference over time of pain-related disability between the two conditions. Other outcome measures will include health-related quality of life, illness perceptions, pain self-efficacy, app system usage data, productivity loss, and health care expenses. RESULTS The study was approved by the local Medical Research Ethics Committee in October 2019. As of March 20, 2020, we have recruited 88 patients. CONCLUSIONS This study will be the first step in systematically evaluating the effectiveness and efficiency of the AGRIPPA app. After 3 years of development and feasibility testing, this formal evaluation will help determine to what extent the app will influence the maintenance of treatment gains over time. The outcomes of this trial will guide future decisions regarding uptake in clinical practice. CLINICALTRIAL Netherlands Trial Register NL8076; https://www.trialregister.nl/trial/8076 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/18632

Oncology providers’ evaluation of the use of a prostate cancer treatment decision aid versus usual information provision: Results from the PCPCC trial

2017 ◽  
Vol 5 (4) ◽  
pp. 433 ◽  
Author(s):  
Maarten Cuypers ◽  
Romy E D Lamers ◽  
Paul J M Kil ◽  
Lonneke V Van de Poll-Franse ◽  
Marieke De Vries
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Decision Aid ◽  
Controlled Trial ◽  
Treatment Decision ◽  
Information Provision ◽  
Care Providers ◽  
Online Questionnaire ◽  
Prostate Cancer Treatment ◽  
Standard Information

Objective: To compare care providers’ evaluations of an online prostate cancer treatment decision aid (DA) to an evaluation of usual information routines.Methods: Oncology care providers (urologists and nurses, n=108) enrolled in the intervention (DA) or control (standard information) arm of a cluster randomized controlled trial were invited to fill out an online questionnaire to evaluate working with the DA or to evaluate usual information provision. Response rate was 58% (n=63).  Results: The DA was provided to 368 patients and distributing care providers were supportive of the DA content and usability. Satisfaction (1-10) with the DA or standard information was comparable (M=7.8 vs M=8.1, p=0.14), although in the control arm, care providers perceived that patients already receive too much information. Time barriers were not expected or perceived. All care providers involved felt suitable to distribute DAs. Care providers with DA experience were more supportive of including DAs in clinical guidelines.Conclusion: Care providers were satisfied with the DA and reported no time barriers. However, many care providers are already satisfied with standard information materials and fear overloading patients with information.

scholarly journals Mobile Health App (AGRIPPA) to Prevent Relapse After Successful Interdisciplinary Treatment for Patients With Chronic Pain: Protocol for a Randomized Controlled Trial

10.2196/18632 ◽  
2020 ◽  
Vol 9 (8) ◽  
pp. e18632
Author(s):  
Stefan Elbers ◽  
Jan Pool ◽  
Harriët Wittink ◽  
Albère Köke ◽  
Else Scheffer ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Randomized Controlled Trial ◽  
Mobile Health ◽  
Treatment Program ◽  
Treatment Condition ◽  
Controlled Trial ◽  
Interdisciplinary Treatment ◽  
Randomized Controlled ◽  
Multicenter Randomized Controlled Trial ◽  
Over Time

Background To facilitate adherence to adaptive pain management behaviors after interdisciplinary multimodal pain treatment, we developed a mobile health app (AGRIPPA app) that contains two behavior regulation strategies. Objective The aims of this project are (1) to test the effectiveness of the AGRIPPA app on pain disability; (2) to determine the cost-effectiveness; and (3) to explore the levels of engagement and usability of app users. Methods We will perform a multicenter randomized controlled trial with two parallel groups. Within the 12-month inclusion period, we plan to recruit 158 adult patients with chronic pain during the initial stage of their interdisciplinary treatment program in one of the 6 participating centers. Participants will be randomly assigned to the standard treatment condition or to the enhanced treatment condition in which they will receive the AGRIPPA app. Patients will be monitored from the start of the treatment program until 12 months posttreatment. In our primary analysis, we will evaluate the difference over time of pain-related disability between the two conditions. Other outcome measures will include health-related quality of life, illness perceptions, pain self-efficacy, app system usage data, productivity loss, and health care expenses. Results The study was approved by the local Medical Research Ethics Committee in October 2019. As of March 20, 2020, we have recruited 88 patients. Conclusions This study will be the first step in systematically evaluating the effectiveness and efficiency of the AGRIPPA app. After 3 years of development and feasibility testing, this formal evaluation will help determine to what extent the app will influence the maintenance of treatment gains over time. The outcomes of this trial will guide future decisions regarding uptake in clinical practice. Trial Registration Netherlands Trial Register NL8076; https://www.trialregister.nl/trial/8076 International Registered Report Identifier (IRRID) DERR1-10.2196/18632

Sign in / Sign up

Export Citation Format

Share Document